Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Mellitus Patients (ONTARGET-INDIA)
A Non-Interventional, Multicentre, Prospective, Observational Study to Understand Usage and Effect of Saxagliptin as First Add-On After Metformin in Indian Type 2 Diabetes Patients. (ONTARGET-India)
Sponsor: AstraZeneca
This observational or N/A phase trial investigates Type 2 Diabetes and is currently completed. AstraZeneca leads this study, which shows 9 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed
-
Sep 2024 — Sep 2025 [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2021 — Jul 2024 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
▶ Show 4 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2018 — Apr 2018 [monthly]
Completed NA
-
Mar 2017 — Jan 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jan 2017 — Mar 2017 [monthly]
Active Not Recruiting NA
First recorded
Oct 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ahmedabad, India , Allahābād, India , Amritsar, India , Bangalore, India , Bhopal, India , Chandigarh, India , Chennai, India , Guwahati, India , Hyderabad, India , Hyderebad, India and 20 more locations